MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.42
-0.02
-0.07%
After Hours: 27.42 0 0.00% 16:45 08/07 EDT
OPEN
27.63
PREV CLOSE
27.44
HIGH
29.20
LOW
26.93
VOLUME
516.05K
TURNOVER
--
52 WEEK HIGH
32.18
52 WEEK LOW
4.040
MARKET CAP
1.48B
P/E (TTM)
-8.1038
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MGNX stock price target is 29.00 with a high estimate of 40.00 and a low estimate of 8.00.

EPS

MGNX News

More
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced t
GlobeNewswire · 2d ago
Citigroup Downgrades Macrogenics to Neutral, Raises Price Target to $26
Citigroup analyst Yigal Nochomovitz downgrades Macrogenics (NASDAQ:MGNX) from Buy to Neutral and raises the price target from $25 to $26.
Benzinga · 5d ago
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/31 04:00
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 22:40
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
Conference call scheduled for today at 4:30 p.m. ET.ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therap
GlobeNewswire · 07/30 20:01
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
MacroGenics EPS misses by $0.04, beats on revenue
Seeking Alpha · 07/30 04:00
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About MGNX

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
More

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.